INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Drug Discovery: From Target Identification to AI-Powered Screening

Sanjanavathi N*[1], Sneha V[2]

[1] *Department of Pharmaceutical Regulatory Affairs, JKKMRF College of Pharmacy, Nammakkal*
[2] *Vidya Siri College of Pharmacy, Bengaluru*

ARTICLE INFO

Published: 24 Feb 2026
Keywords:
Drug discovery; Artificial intelligence; Machine learning; Deep learning; Drug development; Pharmacovigilance
DOI:
10.5281/zenodo.18763155

ABSTRACT

Artificial intelligence (AI) is transforming traditional drug development by enabling faster, cost-effective, and more accurate discovery processes. AI-based technologies such as machine learning, deep learning, and predictive modelling help identify drug targets, screen compounds, and optimize lead molecules with greater precision. By analysing large datasets and uncovering patterns often missed by conventional methods, AI minimizes research timelines, reduces development failures, and improves decision-making across preclinical and clinical stages. This review summarizes the major applications, benefits, and future potential of AI in modern drug discovery and development.

INTRODUCTION

Artificial intelligence has emerged as a powerful tool across scientific and healthcare fields, offering new solutions to long-standing challenges in pharmaceutical research. Drug development is traditionally expensive, slow, and resource-intensive, but AI helps overcome these limitations by processing vast biological and chemical datasets with speed and accuracy. Techniques such as machine learning and deep learning support target identification, compound screening, and predictive modelling. By integrating AI into the drug discovery pipeline, the pharmaceutical industry can reduce costs, shorten timelines, and improve success rates.

1. Drug Discovery

1.1 Target Identification and Validation:

The first step in drug discovery is identifying the biological target—usually a protein, enzyme, receptor, or nucleic acid—that plays a vital role in disease development. An ideal target should be druggable, meaning it can bind selectively with a therapeutic molecule, and disease-modifying, meaning its modulation leads to a clinically

***Corresponding Author:** Sanjanavathi N
Address: *Department of Pharmaceutical Regulatory Affairs, JKKMRF College of Pharmacy, Nammakkal*
Email : sanjanadhanvin@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

beneficial effect [1]. Target identification strategies include:

a) **Genomics and Proteomics:** Genomics is the study of the entire genome of an organism and it helps in the identification of disease – causing genes, personalized medicine and drug target discovery. Proteomics is the study of complete set of proteins expressed by a organism. It is helpful in understanding disease mechanisms, drug development and biomarker discovery.

   Genome-wide association studies (GWAS) and proteomic profiling to identify disease-linked biomolecules [2].

b) **Bioinformatics and Systems Biology:** Bioinformatics is the application of computer science, statistics and mathematics to store, analyse, and interpret biological data. Systems biology as a whole, focusing on interactions and networks among genes, proteins and metabolites. Computational modelling of disease pathways to highlight potential intervention points.

c) **Target validation** confirms the causal relationship between the target and the disease. This can be achieved by:

1. **Genetic Approaches:** Knockout or knockdown models, CRISPR-Cas9 editing to assess phenotypic effects [3].

2. **Pharmacological Approaches:** Use of small molecules or biologics to modulate target activity in vitro and in vivo.

Validated targets reduce the risk of late-stage drug development failure and guide the design of screening assays.

1.2 Hit Identification and Lead Optimization

Once a target is validated, researchers focus on identifying "hits"—compounds with measurable activity against the target. Hit Identification Methods include:

a) **High-Throughput Screening (HTS):** It is a rapid, automated testing of large compound libraries against the target. The principle behind this involves robotics, automation and detectors. [4].

b) **Fragment-Based Drug Discovery (FBDD):** Screening of low molecular weight fragments that bind to the target, followed by chemical expansion to improve binding. It helps in the high binding efficiency and better control over molecular properties. [5].

c) **Virtual Screening:** Virtual screening is a computational docking of chemical libraries to predict binding affinity to a biological target. [6].

d) **Natural Product Screening:** It involves screening and isolation of bioactive compounds from plants, microbes, and marine organisms to identify potential drug candidates.

Hit-to-Lead (H2L) Optimization refines hits to improve potency, selectivity, pharmacokinetics (ADME), and safety. Structure–Activity Relationship (SAR) studies guide chemical modifications. Lead Optimization further enhances drug-like properties, such as oral bioavailability, metabolic stability, and target specificity, while reducing toxicity [7].

1.3 Use of Machine Learning (ML) and Deep Learning in Compound Screening

The integration of AI technologies into drug discovery has revolutionized compound screening by improving hit identification accuracy, reducing

experimental workload, and accelerating timelines.

1.4 Applications in Compound Screening:

a) **Predictive Modelling:** ML algorithms use historical bioactivity data to predict compound–target interactions [8].

b) **Virtual Screening Optimization:** Deep learning models, such as convolutional neural networks (CNNs) and graph neural networks (GNNs), can learn structural patterns from chemical graphs to prioritize promising hits [9].

c) **De Novo Molecule Generation:** Generative adversarial networks (GANs) and reinforcement learning can design novel compounds with optimized properties [10].

d) **Toxicity Prediction:** AI-based QSAR models forecast off-target effects and toxicity profiles before synthesis [11].

By combining experimental screening with AI-driven predictions, pharmaceutical companies can drastically reduce attrition rates and resource expenditure in the early stages of drug discovery.

2. Preclinical Studies: Toxicity Prediction and ADMET Evaluation

Preclinical studies bridge the gap between laboratory drug discovery and clinical trials. They aim to establish a compound's safety profile, biological activity, and pharmacological characteristics before administration to humans [12]. These studies are conducted in vitro (cell lines, biochemical assays) and in vivo (animal models) under Good Laboratory Practice (GLP) guidelines. The objectives of preclinical studies include:

- Determining safe starting doses for clinical trials
- Evaluating pharmacodynamics (PD) — the drug's biological effect
- Assessing pharmacokinetics (PK) — absorption, distribution, metabolism, and excretion
- Identifying potential toxic effects and target organs at risk

2.1 Toxicity Prediction

Toxicity prediction is critical for reducing late-stage failures and minimizing risks to trial participants. Traditionally, toxicity is evaluated using animal models, but recent advances integrate computational toxicology and in silico modelling for early hazard identification. Approaches to Toxicity Prediction:

a) **In Silico Models:** Quantitative structure–activity relationship (QSAR) models predict toxicity based on chemical structure. [11]

b) **Machine Learning & Deep Learning:** AI algorithms trained on large toxicological datasets can forecast potential hepatotoxicity, cardiotoxicity, and genotoxicity before synthesis [13]

c) **High-Content Screening (HCS):** Automated cell-based assays detect early cytotoxic effects, mitochondrial dysfunction, and oxidative stress.

d) **Organs-on-Chips:** Microfluidic devices mimic human organ physiology, enabling prediction of organ-specific toxicity [14]

2.2 ADMET Evaluation

ADMET stands for Absorption, Distribution, Metabolism, Excretion, and Toxicity — critical

parameters for determining a drug's suitability for clinical use [15]

a) **Absorption:** Determines how much of the drug enters systemic circulation—evaluated using Caco-2 cell permeability assays and in situ perfusion models.

b) **Distribution:** Assesses how the drug spreads to tissues and organs, influenced by plasma protein binding and lipophilicity.

c) **Metabolism:** Investigates biotransformation pathways, typically using liver microsomes or recombinant cytochrome P450 enzymes to assess metabolic stability and drug–drug interaction potential.

d) **Excretion:** Examines elimination routes (renal, biliary, or pulmonary) using animal models and in vitro systems.

e) **Toxicity:** Integrates acute, sub-chronic, and chronic toxicity data, including mutagenicity, reproductive toxicity, and carcinogenicity studies.

f) AI-based ADMET prediction tools such as pkCSM and DeepADMET now provide rapid, cost-effective, and accurate predictions, complementing experimental data [16].

2.3 Regulatory Relevance

Regulatory agencies require a comprehensive preclinical dossier in the Investigational New Drug (IND) submission, detailing all toxicity and ADMET findings. Early integration of predictive toxicology reduces attrition rates, shortens timelines, and improves safety in first-in-human trials.

3. Clinical Trials: AI-Driven Innovation

Clinical trials represent one of the most critical and resource-intensive stages of drug development, often accounting for nearly 60–70% of the total research and development (R&D) cost. Despite their importance, trials face persistent challenges such as delayed patient recruitment, poor retention, high costs, and unanticipated adverse events. The integration of artificial intelligence (AI) into clinical research is transforming the way trials are designed, executed, and monitored, ultimately leading to faster, safer, and more efficient pathways from laboratory to patient care.

3.1 Patient Recruitment Optimization

Recruitment is widely regarded as the primary bottleneck in clinical trials. Studies suggest that up to 80% of clinical trials fail to meet their enrolment timelines, often delaying regulatory submissions and market entry. AI systems utilize electronic health records (EHRs), genomic databases, and even social media to identify eligible participants more effectively. Natural language processing (NLP) tools are particularly valuable, as they can analyse unstructured clinical notes and automatically match patients to eligibility criteria. Predictive analytics can also forecast potential dropouts, enabling investigators to intervene early with patient engagement strategies. This not only accelerates trial initiation but also enhances diversity in enrolment, ensuring that underrepresented populations are not excluded from pivotal studies [17,18].

3.2 Trial Design and Simulation

Traditional trial design relies heavily on historical data and expert assumptions, which can be limited and prone to bias. AI introduces data-driven trial design by simulating thousands of potential trial scenarios before real-world implementation. Machine learning algorithms analyse past trial outcomes to optimize inclusion/exclusion criteria,

determine appropriate sample sizes, and identify the most relevant clinical endpoints. Emerging technologies such as digital twins—virtual patient models that mimic human physiology—allow researchers to simulate drug responses in silico, significantly reducing reliance on physical trial participants in early stages. These innovations can reduce trial failures, save costs, and accelerate regulatory decision-making [19,20].

3.3 Monitoring Adverse Effects

Ensuring patient safety during clinical trials is paramount. AI-enabled monitoring systems leverage data streams from wearable devices, smartphone applications, and digital biomarkers to provide real-time health tracking. These tools continuously evaluate patient vital signs, drug responses, and lifestyle factors. Advanced anomaly detection models can identify subtle physiological changes that may signal the onset of an adverse drug reaction well before traditional clinical assessments would detect them. Furthermore, AI-driven pharmacovigilance tools automate the reporting and analysis of adverse events, facilitating timely interventions and improving overall safety management during clinical studies [21,22].

In sum, AI-driven recruitment, trial simulation, and safety monitoring are revolutionizing clinical research. By reducing inefficiencies and improving patient outcomes, AI is paving the way for a new era of smarter, faster, and safer clinical trials.

4. Post-Marketing Surveillance (Pharmacovigilance)

Post-marketing surveillance (PMS), or pharmacovigilance, is an indispensable component of the drug development life cycle. While clinical trials are carefully designed, they often include only a few thousand participants under controlled conditions. This limits the detection of rare adverse drug reactions (ADRs), long-term side effects, and interactions in special populations such as children, pregnant women, or elderly patients. Once a drug is approved, it enters real-world environments where millions of patients may be exposed—making continuous safety monitoring essential.

The global scale of pharmacovigilance generates an enormous volume of heterogeneous data from diverse sources, including spontaneous reporting systems, electronic health records (EHRs), insurance claims, clinical notes, scientific literature, wearable devices, and even patient-generated content from social media. AI offers the ability to integrate, clean, and analyse these complex datasets to generate timely, reliable safety insights.

4.1 Signal Detection

Signal detection refers to the identification of new, unexpected, or rare associations between drugs and adverse effects. Traditional methods—such as disproportionality analysis in spontaneous reporting systems—are valuable but limited by under-reporting (only 5–10% of ADRs are typically reported), delays in reporting, and difficulty distinguishing true signals from noise.

AI-driven models overcome these limitations by:

- **Automated Data Mining:** Machine learning algorithms scan millions of adverse event reports and automatically prioritize those with high signal probability.
- **Pattern Recognition:** Deep learning models identify subtle associations in data that may be missed by traditional statistical approaches.

- **Bayesian Neural Networks:** These models have been successfully applied to detect ADR signals earlier than conventional techniques, reducing the risk of delayed regulatory interventions [19].

- **Social-Media & Online Forums:** NLP algorithms analyse patient discussions and online reviews to capture early warning signs of ADRs. For example, patients often report side effects on forums before they appear in official reports, making this as valuable supplementary data stream [23].

By combining traditional statistical methods with AI-driven insights, pharmacovigilance is evolving into a proactive system rather than a reactive one.

4.2 Real-World Data Analytics

Real-world data (RWD) provides a more complete picture of drug safety and effectiveness across diverse populations. Unlike clinical trials, which may exclude patients with comorbidities or polypharmacy, RWD reflects actual usage in broader and more complex healthcare settings.

AI enhances the utility of RWD in several ways:

- **Electronic Health Records (EHRs):** ML algorithms process structured (lab values, diagnoses) and unstructured (physician notes, discharge summaries) data to detect ADRs and drug interactions.

- **Wearable Devices & Digital Biomarkers:** Continuous monitoring through smartwatches and biosensors generates high-frequency health data. AI models analyse these data streams to detect subtle physiologic changes that may indicate drug-related complications [21].

- **Insurance Claims & Registries:** Predictive analytics models evaluate treatment outcomes, hospitalizations, and long-term risks by linking prescription data with clinical outcomes.

- **Population-Level Insights:** AI enables stratification of ADR risk across demographics, genetic subgroups, and geographic populations—contributing to precision pharmacovigilance.

Such analytics not only protect patient safety but also provide evidence for regulatory actions such as label modifications, usage restrictions, or—when necessary—drug withdrawal.

4.3 Regulatory Integration

Regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) are increasingly adopting AI-driven tools to enhance post-marketing safety surveillance. For example, the FDA Sentinel Initiative integrates data from over 100 million patients to identify and evaluate safety signals in near real time [24]. AI applications allow regulators to move from passive surveillance systems to active monitoring frameworks that continuously analyse patient safety.

4.4 Broader Impact

AI in pharmacovigilance represents a paradigm shift:

- From manual reporting → to automated, real-time monitoring

- From small-scale signal detection → to global-scale data integration

- From reactive safety measures → to predictive and preventive interventions

Ultimately, AI-driven pharmacovigilance reduces patient risk, enhances regulatory confidence, and contributes to safer healthcare ecosystems worldwide.

5. Applications of AI Tools & Technologies

The practical applications of artificial intelligence (AI) in drug development are diverse and span the entire pipeline, from early discovery to post-market surveillance. Multiple AI approaches—including machine learning (ML), deep learning (DL), natural language processing (NLP), and neural networks—have been successfully deployed to accelerate timelines, reduce costs, and improve decision-making in pharmaceutical research. The adoption of specialized AI platforms such as IBM Watson, AlphaFold, and Benevolent AI further illustrates how these tools are transforming traditional research models into data-driven, intelligent systems.

5.1 Machine Learning (ML)

Machine learning algorithms form the backbone of AI in drug discovery and development. By training on large-scale biomedical datasets, ML models can:

- Predict drug–target interactions and off-target binding.
- Estimate pharmacokinetic and pharmacodynamic properties.
- Support virtual screening by narrowing down large compound libraries to the most promising candidates.
- Aid in adaptive clinical trial design by forecasting trial outcomes and optimizing patient stratification.

ML-based quantitative structure–activity relationship (QSAR) models have been widely applied in toxicity prediction and ADMET assessment, demonstrating significant improvements over traditional statistical methods [1].

5.2 Deep Learning (DL)

Deep learning, a subset of ML, leverages neural network architectures with multiple layers to capture complex, non-linear patterns in data. DL has shown particular success in:

- **Molecular property prediction:** Graph neural networks (GNNs) model chemical structures as graphs, enabling highly accurate binding affinity predictions.
- **Image analysis:** Convolutional neural networks (CNNs) assist in analysing histopathology slides, radiological images, and high-content screening outputs.
- **De novo drug design:** Generative adversarial networks (GANs) and reinforcement learning algorithms can design novel compounds with optimized efficacy and safety profiles [2,3].

Notably, DL-powered platforms have already generated drug candidates that progressed into clinical trials, highlighting its translational value.

5.3 Natural Language Processing (NLP)

The biomedical literature grows exponentially, making it difficult for researchers to keep pace. NLP tools extract meaningful information from unstructured text sources, including:

- **Scientific publications and patents:** NLP accelerates knowledge discovery by mining chemical–biological relationships.

- **Electronic health records (EHRs):** Algorithms analyse physician notes to identify potential trial participants and detect ADRs.

- **Social media and forums:** Patient-reported outcomes provide early safety signals and insights into drug tolerability [4].

AI-driven NLP systems are particularly valuable in pharmacovigilance, where rapid information extraction from text-based reports reduces manual workload.

5.4 Neural Networks

Neural networks (NNs) mimic the architecture of the human brain and are particularly suited for modelling complex, multi-dimensional biomedical data. Beyond deep learning, NNs are applied in:

- Predicting protein–ligand interactions.

- Modelling drug synergy in combination therapies.

- Classifying phenotypic responses from large-scale biological assays.

Bayesian neural networks also support uncertainty quantification in predictions, which is crucial in high-stakes applications such as toxicity forecasting [5].

5.5 Real-World Examples of AI Platforms

- **IBM Watson for Drug Discovery:** Uses NLP and ML to analyse biomedical literature and generate hypotheses about novel therapeutic targets. Pharmaceutical companies have used Watson to accelerate biomarker identification and repurposing efforts [6].

- **AlphaFold (DeepMind):** Revolutionized structural biology by accurately predicting 3D protein structures, dramatically reducing reliance on time-intensive methods such as X-ray crystallography. This breakthrough has significantly advanced target identification and validation [7].

- **Benevolent AI:** Employs AI-powered knowledge graphs to integrate chemical, biological, and clinical data. The company is known for successfully identifying baricitinib as a repurposed treatment option for COVID-19, later authorized for emergency use [8]

6. Case Studies and Success Stories in AI-Driven Drug Discovery

6.1 AI Success in Drug Repurposing: The COVID-19 Example

The COVID-19 pandemic accelerated the application of artificial intelligence (AI) in identifying repurposable drugs with potential antiviral activity. AI algorithms analysed large-scale biomedical datasets—such as gene expression profiles, molecular docking simulations, and chemical structure libraries—to pinpoint compounds capable of inhibiting SARS-CoV-2 replication.

A notable example is Baricitinib, originally approved for rheumatoid arthritis, which was repurposed for COVID-19 using machine learning–based network pharmacology. Researchers at Benevolent AI applied graph-based reasoning and literature mining to predict that Baricitinib could block viral entry by inhibiting AAK1 and GAK kinases, crucial for viral endocytosis. This computational prediction was experimentally validated and led to rapid inclusion in global clinical trials and subsequent FDA

Emergency Use Authorization (EUA) for hospitalized COVID-19 patients [25].

Similarly, Remdesivir and Favipiravir were identified through AI-assisted in silico screening platforms integrating molecular docking, QSAR modelling, and high-throughput simulations, reducing discovery time dramatically compared to traditional methods [26].

AI repurposing tools such as DeepChem, Pharm AI, and COVID-19 Knowledge Graphs demonstrated how deep learning can uncover novel target–compound relationships hidden within existing pharmacological datasets. These efforts not only shortened the drug discovery cycle from years to weeks but also offered a blueprint for future pandemic response strategies.

6.2 AI-Assisted Drugs That Reached Clinical Trials or Approval

AI has progressed from repurposing to de novo design. This led to innovative molecules for drugs that proceeded to trials.

(1) DSP-1181 (Ex Scientia & Sumitomo D

This was the first molecule designed with the aid of AI, making its entry into human clinical trials in the year 2020 as a 5-HT1A receptor antagonist for the treatment of obsessive-compulsive disorder (OCD). Ex Scientia's deep learning techniques enabled the company to achieve potency, selectivity, and pharmacokinetic profiles for DSP-1181 in 12 months, which would take 4-5 years conventionally.

(2) ISM001-055

ISM001-055 was developed by the use of deep generative learning based on molecular docking and reinforcement learning and is focused on being an anti-fibrotic drug undergoing Phase I clinical trials by 2021. Using Insilico's AI system, target identification and nomination of a drug to clinical trials took under 18 months [28]. This marked the first fully AI-discovered drug to enter human clinical trials

(3) BEN-2293 (Benevolent AI)

BEN-2293 was developed for atopic dermatitis. In 2023, it began Phase II trials. Benevolent AI's knowledge graphs and deep learning models combined data from genomics, proteomics, and literature to identify potential targets for inflammatory pathways to improve compound design by optimizing leads [29].

These case studies emphasize collectively that AI has a significant ability to cut down development time, expenditure, and attrition. It not only marks a transition in the application area of AI but also indicates that AI is being used not just for computation but for innovation.

7. Benefits of AI in Drug Development

Artificial intelligence (AI) is transforming traditional pharmaceutical research and development (R&D) by accelerating discovery timelines, reducing costs, and enhancing precision and efficiency across the entire drug development pipeline. By integrating computational intelligence with biological data, AI enables scientists to make data-driven decisions faster and more accurately than ever before.

7.1 Faster Timelines

AI dramatically shortens the time required for identifying drug targets, screening potential compounds, and optimizing leads. Traditional drug discovery can take 10–15 years, but AI-assisted processes can reduce early-stage discovery to under 2 years [26]

Machine learning (ML) algorithms can rapidly analyse complex datasets—such as genomics, proteomics, and cheminformatics—to predict drug–target interactions, thereby minimizing experimental trial-and-error.

For example, Ex Scientia's DSP-1181, the first AI-designed drug to enter clinical trials, was identified and optimized in 12 months, compared to the typical 4–5 years using conventional methods (Mak & Pichika, 2019). Similarly, Insilico Medicine's ISM001-055 progressed from target discovery to preclinical candidate nomination in just 18 months [28]. These examples highlight AI's ability to compress discovery and preclinical stages, enabling faster transitions to clinical testing and improving the overall success rate of pharmaceutical innovation.

7.2 Cost Reduction

Drug development traditionally incurs billions of dollars in R&D expenses due to high attrition rates, prolonged testing, and redundant experimental workflows. AI mitigates these challenges by prioritizing the most promising candidates early, thereby reducing the number of failed compounds entering costly clinical phases [27]

Advanced predictive models can forecast compound toxicity, bioavailability, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles, eliminating unsuitable molecules before lab synthesis [30]

According to industry analyses, AI-driven approaches can potentially reduce discovery costs by up to 40–60%, primarily through automation, in silico screening, and virtual modelling [26]. AI also supports process automation in clinical trial design, patient recruitment, and pharmacovigilance, further minimizing operational costs while maintaining data accuracy and regulatory compliance [31]

7.3 Precision and Efficiency

AI brings higher precision by allowing integrations of data across various biological layers-from genomic to transcriptomic to clinical data-to offer comprehensive biological insights.

These deep learning models can identify subtle molecular patterns perhaps missed by traditional algorithms or human intuition, enabling more accurate target identification and mechanistic understanding.

In AI-powered clinical development, it enhances trial efficiency with predictive analytics for patient stratification, real-time monitoring of adverse events, and adaptive trial simulations [33]. These tools optimize study designs and ensure trials enroll the right patients at the right time under the right conditions for increased success rates and reduced dropouts.

In all, AI acts like an integrative engine: it makes the process not only faster and cheaper but also scientifically precise, hence driving the pharmaceutical industry toward a new era of evidence-based intelligent drug design.

8. Challenges and Limitations of AI in Drug Development

Although AI has great potential in the area of drug discovery, there are several significant challenges facing the integration of AI in pharmacological innovation. These challenges have to be met if one aims to ensure the use of AI in drug development meets the required standards**.**

8.1 Data Quality and Availability

Overreliance on artificial intelligence models is directly related to the quality of their training data. Working in drug development, the data used in models might be generated or collected from diverse sources such as preclinical models, chemical repositories, and patient data, leading to biased and incomplete data sources.

Incomplete annotation, non-standardization of formats of biological data, and errors in experimental results may result in erroneous model training and predictions [35].

Further, the data silos in pharmaceutical companies hinder access to large-scale data for the credible development of AI models since open-access, high-quality data is not available for validation and cross-validation of AI models, thus affecting scientific advancements and collaboration.

8.2 Ethical Concerns and Bias

The potential for bias exists in the datasets that the AI systems are trained on. For example, the demographics in healthcare datasets may not adequately represent the populations in question. As a result, the predictions concerning the effectiveness or safeness of a drug could be influenced by this bias [37].

Moreover, the “black box” problem associated with deep learning algorithms has raised concerns about transparency, as it is hard for both policymakers and healthcare providers to understand the mechanism used by certain AI algorithms in making predictions [38].

Ethical concerns also encompass issues of privacy and consent in relation to genetic information that could be mishandled. To address such matters, there is a need for the use of explainable artificial intelligence and following privacy regulations such as the General Data Protection Regulation and Health Insurance Portability and Accountability Act or HIPAA [39].

8.3 Regulatory Barriers

The scenario is still unfolding regarding adapting to AI-enabled tools used in drug discovery. This includes the initiation of frameworks offered by various governing bodies, such as the FDA in the United States, EMA, which translate to European Medicines Agency, and so forth, regarding digital health technology. However, AI guidelines regarding validation, transparency, or accountability are still unexplored [40].

The adaptive and learning abilities in the algorithms make it difficult for regulatory approval because they are able to learn and change their behaviour after they have been implemented [41]. Regulatory bodies are faced with the challenge of balancing safety and innovation in designing criteria for assessment of performance and reproducibility of algorithms.

8.4 Lack of Skilled Workforce

There is an immediate need for a multidisciplinary workforce qualified in data science, bioinformatics, pharmacology, and regulatory science for AI in pharmaceutical R&D. Unfortunately, there is an alarming scarcity of professionals who can translate between AI models and biomedically relevant interpretations globally today [42].

Thus, this talent gap is an obstacle in both the adoption and scalability of AI technology in pharma companies and in research institutions. To tackle this issue, it is essential that academic collaborations and pharma companies emphasize education in AI literacy and collaborations across

domains to build a next generation of drug developers well-versed in AI.

Conclusion

At the end of the day, despite the unprecedented benefits that AI brings for speeding up the drug development process, it needs to be successfully developed in a manner that overcomes the difficulties that currently exist in the areas of data integrity, ethics, regulation, and human expertise.

9. Future Perspectives

The future of artificial intelligence in pharmacology will bring about a paradigm shift by converging the latest computational models, personalized medicine, and other fields like bioengineering and nanotechnology. This is because the pharmaceutical industry is on the route to embracing the digital transformation and will thus be shaped by the new wave of converging technologies.

9.1 Integration with Quantum Computing

The next frontier in speeding up AI-assisted drug discovery is quantum computing. Conventional computers are struggling to represent quantum mechanical calculations on a large molecular level due to the large space that needs to be processed. Quantum computing processes information using qubits, which enable simultaneous exploration of multiple molecular configurations [43].

When coupled with algorithms of Artificial Intelligence, the process of simulating protein/ligand interactions, optimization of molecular conformation, and binding affinities can be done by Quantum Computing. This has an unparalleled level of accuracy

Early studies have shown the ability of quantum machine learning algorithms in screening compounds and designing novel molecules, rendering a possible solution for the limitations of conventional in-silico simulations in drug design [45].

"As quantum hardware continues to evolve and mature, it is with AI could revolutionize computational pharmacology, enabling near-instantaneous drug candidate evaluation and reducing the discovery timeline to mere months.

9.2 Personalized and Precision Medicine

Artificial Intelligence is core to the development of Precision Medicine, which uses a unique genetic, proteomic, and clinical profile to personalize therapeutics for an individual [46].

Machine learning models are able to integrate multi-omics data, such as genomics, transcriptomics, and metabolomics, to enable the prediction of disease risks, treatment efficacies, and side effects for individual patients [47].

Machine learning models make it easier to find biomarkers, detect interactions between drugs and genes, and optimize drug doses through real-world evidence (RWE) [48]. Such personalization increases the effectiveness of treatments and reduces toxicity.

Cancer treatment, for instance, sees the use of artificial intelligence in the design of precise personalized therapeutic approaches using the analysis of genomics of tumours. With the growth of data ecosystems, the use of artificial intelligence will keep promoting a paradigm shift from development targeting populations to development that is personalized.

9.3 AI in Combination with Synthetic Biology and Nanotechnology

The integration of Artificial Intelligence with Synthetic Biology and Nanotechnology brings new possibilities with smart therapeutic agents.

In the field of synthetic biology, AI algorithms help design gene circuits, pathways, and genetically engineered microorganisms to produce valuable pharmaceuticals [49]. Deep learning models are being applied to foresee enzyme functions, biosynthetic routes, and genetic components for precision biomanufacturing [50].

On the other hand, in the field of nanotechnology, the use of AI helps in the rational design of nanocarriers according to specified physicochemical characteristics for drug delivery purposes [51]. By processing huge information sets regarding the composition of nanoparticles and biological outcomes, the potential for the biodistribution, targeting ability, and toxicity of the nanoparticles can be predicted—that is, the expedited development of next-generation nanomedicines. The collaboration between AI technology, synthetic biology, and nanotech will promote the development of intelligent therapeutic systems that are capable of detecting biological signals and delivering drugs to specified locations in space and time.

Artificial intelligence, together with advancements in synthetic biology and nanotechnology, is on the verge of unlocking new possibilities for ‘smart’ drugs.

Artificial intelligence algorithms are being employed in the design of gene circuits, metabolic paths, and biodegradation microorganisms for the production of high-value

DISCUSSION

AI is reshaping drug development by improving efficiency at every stage—from identifying therapeutic targets to designing clinical trials. Machine learning algorithms enable rapid screening of compound libraries, prediction of drug–target interactions, and optimization of lead molecules. Deep learning models enhance accuracy in toxicity prediction and pharmacokinetic analysis, reducing failures in later stages. In clinical research, AI supports patient selection, trial monitoring, and outcome prediction, ensuring more reliable results. Although challenges such as data quality, ethical concerns, and validation requirements remain, AI’s growing capabilities indicate a strong future role in accelerating and improving drug development

CONCLUSION

Artificial intelligence (AI) has become a transformative force in pharmaceutical research and development, offering novel solutions to long-standing challenges in drug discovery, preclinical testing, and clinical optimization. By leveraging vast biological datasets and advanced computational models, AI has significantly accelerated target identification, compound screening, and clinical decision-making, thereby reducing both time and cost in bringing new therapies to patients.

The integration of AI across every stage of drug development—from predictive modelling and toxicity assessment to clinical trial monitoring and post-market surveillance—demonstrates its capacity to convert data into actionable scientific insights. Moreover, the convergence of AI with quantum computing, personalized medicine, synthetic biology, and nanotechnology will further enhance its precision and scalability in the coming years.

However, the true potential of AI can only be realized through responsible and ethical

implementation. Ensuring data integrity, algorithmic transparency, regulatory compliance, and a skilled interdisciplinary workforce is crucial for maintaining scientific trust and patient safety. The future of drug development lies not merely in automation, but in intelligent collaboration between human expertise and artificial intelligence.

In essence, AI represents not just a technological advancement but a paradigm shift—transforming drug development into a more efficient, ethical, and evidence-driven process that prioritizes human health above all.

REFERENCES

1. Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239–1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x
2. Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013). Validating therapeutic targets through human genetics. Nature Reviews Drug Discovery, 12(8), 581–594. https://doi.org/10.1038/nrd4051
3. Zhou, Y., Zhu, S., Cai, C., Yuan, P., Li, C., Huang, Y., & Wei, W. (2014). High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature, 509(7501), 487–491. https://doi.org/10.1038/nature13166
4. Macarron, R., Banks, M. N., Bojanic, D., et al. (2011). Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery, 10(3), 188–195. https://doi.org/10.1038/nrd3368
5. Murray, C. W., & Rees, D. C. (2009). The rise of fragment-based drug discovery. Nature Chemistry, 1(3), 187–192. https://doi.org/10.1038/nchem.217
6. Shoichet, B. K. (2004). Virtual screening of chemical libraries. Nature, 432(7019), 862–865. https://doi.org/10.1038/nature03197
7. Keserű, G. M., & Makara, G. M. (2009). The influence of lead discovery strategies on the properties of drug candidates. Nature Reviews Drug Discovery, 8(3), 203–212. https://doi.org/10.1038/nrd2796
8. Vamathevan, J., Clark, D., Czodrowski, P., et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5
9. Stokes, J. M., Yang, K., Swanson, K., et al. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688–702.e13. https://doi.org/10.1016/j.cell.2020.01.021
10. Zhavoronkov, A., et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 37(9), 1038–1040. https://doi.org/10.1038/s41587-019-0224-x
11. Mayr, A., Klambauer, G., Unterthiner, T., & Hochreiter, S. (2016). DeepTox: Toxicity prediction using deep learning. Frontiers in Environmental Science, 3, 80. https://doi.org/10.3389/fenvs.2015.0008
12. FDA. (2020). Step 2: Preclinical Research. U.S. Food and Drug Administration. https://www.fda.gov
13. Xu, Y., Dai, Z., Chen, F., et al. (2022). Deep learning for toxicity prediction: From chemical structure to in vivo endpoints. Computational and Structural Biotechnology Journal, 20, 6048–6064. https://doi.org/10.1016/j.csbj.2022.10.025
14. Ronaldson-Bouchard, K., & Vunjak-Novakovic, G. (2018). Organs-on-a-Chip: A fast track for engineered human tissues in drug development. Cell Stem Cell, 22(3), 310–324. https://doi.org/10.1016/j.stem.2018.02.011

15. Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
16. Wu, Z., Yang, K., Liu, X., et al. (2023). DeepADMET: A deep learning-based ADMET prediction platform. Briefings in Bioinformatics, 24(3), bbad122. https://doi.org/10.1093/bib/bbad122
17. Weng C, Li Y, Ryan P, et al. A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records. Applied Clinical Informatics. 2014;5(2):463–479. doi:10.4338/ACI-2013-12-RA-0104
18. Bunnik EM, Aarts N, van de Vathorst S. The changing role of patient information in clinical trials. Drug Discovery Today. 2017;22(8):1218–1223. doi:10.1016/j.drudis.2017.04.005
19. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. European Journal of Clinical Pharmacology. 1998;54(4):315–321. doi:10.1007/s002280050466
20. Lim G, McCulloch CE, Ruby J, et al. Artificial intelligence for clinical trial design. Trends in Pharmacological Sciences. 2022;43(4):282–294. doi:10.1016/j.tips.2022.01.003
21. Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: hype and hypothesis. Clinical Pharmacology & Therapeutics. 2018;104(1):42–52. doi:10.1002/cpt.. 966
22. Siah KW, Lo AW, Shih C, Wong CH. Probability of success in clinical drug development: Predicting outcomes using AI-based analytics. Biostatistics. 2021;22(2):300–316. doi:10.1093/biostatistics/kxz030
23. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539–546. doi:10.1038/clpt.2013.24
24. Ball R, Robb M, Anderson SA, Dal Pan G. The FDA's Sentinel Initiative—A comprehensive approach to medical product surveillance. Clin Pharmacol Ther. 2016;99(3):265–268. doi:10.1002/cpt.320
25. Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Stebbing, J. (2020). Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet, 395(10223), e30-e31.
26. Zhavoronkov, A., et al. (2020). Artificial intelligence in drug discovery and development: Applications, limitations, and future directions. Nature Biotechnology, 38, 122–128. https://doi.org/10.1038/s41587-019-0324-8
27. Mak, K.-K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today, 24(3), 773–780. https://doi.org/10.1016/j.drudis.2018.11.014
28. Zhavoronkov, A., et al. (2022). Target discovery and AI-driven development of the fibrosis drug candidate ISM001-055. Nature Biotechnology, 40, 1341–1347. https://doi.org/10.1038/s41587-022-01318-3
29. BenevolentAI. (2023). BenevolentAI announces progress of BEN-2293 clinical program for atopic dermatitis [Press release]. https://www.benevolent.com/news

30. Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., ... & Collins, J. J. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688–702.e13. https://doi.org/10.1016/j.cell.2020.01.021
31. Breschi, A., Schneider, R., & Gonzales, R. (2021). Artificial intelligence in clinical development: Challenges and opportunities. Nature Reviews Drug Discovery, 20(8), 573–589. https://doi.org/10.1038/s41573-021-00263-6
32. Jiang, M., Li, Z., & Chen, T. (2021). Deep learning for biological data integration in drug discovery. Briefings in Bioinformatics, 22(6), bbab393. https://doi.org/10.1093/bib/bbab393
33. Wang, Y., Xu, Y., Luo, Y., & Zhao, Z. (2021). Artificial intelligence applications in clinical trials: A systematic review. Journal of Clinical Medicine, 10(4), 897. https://doi.org/10.3390/jcm10040897
34. Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318. https://doi.org/10.1001/jama.2017.18391
35. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7
36. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2020). The rise of deep learning in drug discovery. Drug Discovery Today, 25(9), 1668–1676. https://doi.org/10.1016/j.drudis.2020.06.010
37. Rajkomar, A., Hardt, M., Howell, M. D., Corrado, G., & Chin, M. H. (2019). Ensuring fairness in machine learning to advance health equity. Annals of Internal Medicine, 169(12), 866–872. https://doi.org/10.7326/M18-1990
38. Floridi, L., Cowls, J., King, T. C., & Taddeo, M. (2020). How to design AI for social good: Seven essential factors. Science and Engineering Ethics, 26(3), 1771–1796. https://doi.org/10.1007/s11948-020-00213-5
39. Tjoa, E., & Guan, C. (2020). A survey on explainable artificial intelligence (XAI): Toward medical XAI. IEEE Transactions on Neural Networks and Learning Systems, 32(11), 4793–4813. https://doi.org/10.1109/TNNLS.2020.3027314
40. Goodman, K. W., Berner, E. S., Dilsizian, S. E., & Wong, J. B. (2020). Artificial intelligence in healthcare: Challenges for regulatory approval. The American Journal of Bioethics, 20(11), 9–17. https://doi.org/10.1080/15265161.2020.1819469
41. Shortliffe, E. H., & Sepúlveda, M. J. (2018). Clinical decision support in the era of artificial intelligence. JAMA, 320(21), 2199–2200. https://doi.org/10.1001/jama.2018.17163
42. Marcus, G. (2020). The next decade in AI: Four steps towards robust artificial intelligence. arXiv preprint, arXiv:2002.06177.
43. Bauer, B., Bravyi, S., Motta, M., & Chan, G. K.-L. (2020). Quantum algorithms for quantum chemistry and materials science. Chemical Reviews, 120(22), 12685–12717. https://doi.org/10.1021/acs.chemrev.9b00829
44. Mitarai, K., Negoro, M., Kitagawa, M., & Fujii, K. (2021). Quantum circuit learning. Physical Review A, 98(3), 032309. https://doi.org/10.1103/PhysRevA.98.032309
45. Li, Y., Peng, J., & Zhong, H. (2021). Quantum machine learning in drug discovery: Applications and challenges. Drug Discovery Today, 26(12), 2751–2760. https://doi.org/10.1016/j.drudis.2021.07.005

46. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7
47. Johnson, K. W., et al. (2021). Artificial intelligence in cardiology: Applications, challenges, and perspectives. Nature Reviews Cardiology, 18(8), 505–524. https://doi.org/10.1038/s41569-021-00529-7
48. Esteva, A., et al. (2021). Deep learning-enabled medical computer vision. Nature Medicine, 27(9), 1421–1429. https://doi.org/10.1038/s41591-021-01460-7
49. Nielsen, J., & Keasling, J. D. (2016). Engineering cellular metabolism. Cell, 164(6), 1185–1197. https://doi.org/10.1016/j.cell.2016.02.004
50. Jervis, A. J., Carbonell, P., Taylor, S., Sung, R., Dunstan, M. S., Robinson, C. J., ... & Faulon, J.-L. (2019). Machine learning of designed translational control allows predictive pathway optimization in Escherichia coli. ACS Synthetic Biology, 8(1), 127–136. https://doi.org/10.1021/acssynbio.8b00227
51. Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2022). Current trends and challenges in the clinical translation of nanomedicines. Advanced Drug Delivery Reviews, 182, 114123. https://doi.org/10.1016/j.addr.2021.114123

HOW TO CITE: Sanjanavathi N, Sneha V, Drug Discovery: From Target Identification to AI-Powered Screening, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 2, 4024-4040. https://doi.org/10.5281/zenodo.18763155